Lipitor Warnings Fail To Adequately Disclose Type 2 Diabetes Side Effects
Evidence continues to emerge that suggests Pfizer knew or should have known about the link between Lipitor and diabetes for years, yet the drug maker failed to adequately warn about the risk of problems or the importance of monitoring blood glucose levels while using the medication.
Although the Lipitor warning label was updated in February 2012, it continues to be inadequate and fails to provide sufficient information for consumers or the medical community.
▸ More Information: Lipitor Type 2 Diabetes Side Effects
The lawyers at Saiontz & Kirk, P.A. are reviewing potential Lipitor lawsuits for women with diabetes. All claims are being handled on a contingency fee basis, which means that there are no out of pocket expenses to hire our law firm and we receive no attorney fees or expenses unless we are successful obtaining a recovery in your case. Request a free consultation and claim evaluation.
Link Between Lipitor and Diabetes
Have You Been Diagnosed with Type 2 Diabetes After Using Lipitor?
Lipitor (atorvastatin) was introduced in 1996 by Warner Lambert, and was subsequently acquired by Pfizer. It is part of a class of cholesterol drugs known as statins, which have been used by millions of Americans, with Lipitor being one of the most popular brand name medications in the world. The blockbuster sales of Lipitor have helped Pfizer become one of the largest pharmaceutical companies in the world.
A number of studies have suggested a link between diabetes and Lipitor use, and most of this information has been known or knowable by Pfizer for years.
This month, a study published in the British Medical Journal (BMJ) suggests that users of Lipitor may be 22% more likely to be diagnosed with diabetes than those not given the drug, yet Pfizer has aggressively promoted Lipitor as safe and effective without adequately warning about the potential side effects.
In February 2012, amid emerging concerns about diabetes and other health problems from Lipitor, Pfizer updated the label at the request of the FDA. However, the label remains confusing and insufficient to reflect the potential risk associated with the medication.
The only reference to the diabetes risk added to the Lipitor label was placed in the “Warnings and Precautions” section:
If Pfizer had not placed their desire for massive profits before the safety of consumers by withholding information about the link between Lipitor and diabetes, thousands of women who have subsequently developed type 2 diabetes may have avoided the disease by choosing to avoid use of the cholesterol medication or by monitoring for changes in the blood sugar levels while taking Lipitor.